---
title: "De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275923532.md"
description: "TD Cowen analyst Joseph Thome has maintained a Buy rating on DRUG stock, citing strong clinical performance of BMB-101 in treating absence epilepsy and developmental and epileptic encephalopathies. He anticipates pivotal global trials in 2026 and has raised peak sales estimates. Thome also highlights potential in the Prader-Willi syndrome franchise and believes the current share price does not reflect the company's de-risked pipeline. Robert W. Baird also supports this with a Buy rating and a $126 price target."
datetime: "2026-02-13T15:45:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275923532.md)
  - [en](https://longbridge.com/en/news/275923532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275923532.md)
---

# De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise

TD Cowen analyst Joseph Thome has maintained their bullish stance on DRUG stock, giving a Buy rating today.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Joseph Thome has given his Buy rating due to a combination of factors tied to both clinical performance and valuation. He highlights that BMB-101 delivered stronger-than-expected seizure reductions in absence epilepsy and developmental and epileptic encephalopathies, with a safety profile in line with the 5-HT2C class, supporting the start of global registrational trials in 2026 and leading him to raise his peak sales assumptions materially in both indications.

Thome also underscores the added upside from the Prader-Willi syndrome franchise, where a proof-of-concept study with BMB-101 and a planned Phase I for follow-on asset BMB-105 are designed to accelerate time to market while addressing unmet needs across appetite, weight, and behavioral domains. Coupled with a solid cash position and strong support from key opinion leaders, he views 2026 as a pivotal execution year and believes the current share price does not adequately reflect the company’s de-risked pipeline and expanded commercial potential, justifying his Buy recommendation.

In another report released today, Robert W. Baird also maintained a Buy rating on the stock with a $126.00 price target.

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [DRUG.US](https://longbridge.com/en/quote/DRUG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)